Repligen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.3%. The stock now trades at $163.29, marking a 36.5% gain. This was partly due to its solid ...

Sartorius and Repligen launched an integrated bioreactor system that incorporates Repligen XCell ® ATF upstream intensification technology into Sartorius’ Biostat STR ® bioreactor. The goal is to ...

Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...

WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results , with sales up 14.8% year on year to $182.4 million. The company’s full-year revenue guidance of $725 ...

Repligen Corporation (NASDAQ:RGEN), is not the largest company out there, but it saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGS. While good news for ...

Repligen RGEN shares ended the last trading session 4.3% higher at $193.40. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Sands Capital, an investment management company, released its “Sands Capital Global Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global Growth adopts a ...

Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use ...

We recently published Top 10 Stock Recommendations You Can’t Miss Amid Growing AI Bubble Fears. Repligen Corporation (NASDAQ:RGEN) is one of the top recommended stocks. Dan Veru, Palisade Capital ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here. The fund was up 3.58% (Institutional ...

WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected ...